AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Dr. Reddy’s Laboratories–An Efficient and Telescopic Process for Valsartan, an Angiotensin II Receptor Blocker

 PROCESS  Comments Off on Dr. Reddy’s Laboratories–An Efficient and Telescopic Process for Valsartan, an Angiotensin II Receptor Blocker
Jun 042013
 

Abstract Image

An efficient, telescopic, and scalable process for an antihypertensive drug substance, valsartan with an overall yield of 58%, and 99.9% purity is described. A simple, and safe process is developed for the recovery of tributyltin chloride from the tributyltin hydroxide, byproduct formed in the tetrazole ring construction, and reused in the synthesis of valsartan.

Dr. Reddy’s Laboratories

Org. Process Res. Dev., 2012, 16 (4), pp 682–686

DOI: 10.1021/op3000306
Publication Date (Web): March 5, 2012
Share

Clovis Oncology Shares Double on Trial Data for Cancer Drug,CO-1686

 phase 1, Uncategorized  Comments Off on Clovis Oncology Shares Double on Trial Data for Cancer Drug,CO-1686
Jun 042013
 

Colorado-based Clovis said in a statement today. The drug, CO-1686, is in the first of three phases of testing typically required before U.S. regulatory approval.

http://www.businessweek.com/news/2013-06-03/clovis-oncology-shares-almost-double-on-ovarian-drug-trial-data

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

Share

Isis Pharmaceuticals, Inc.announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago

 drugs  Comments Off on Isis Pharmaceuticals, Inc.announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago
Jun 042013
 

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago. Results of the initial dose escalation study in patients with metastatic cancer showed that ISIS-STAT3Rx treatment resulted in partial responses that were durable and prolonged in two out of three patients with diffuse large B-cell lymphoma (DLBCL) who were refractory to prior chemotherapy treatments. Isis and AstraZeneca are currently evaluating ISIS-STAT3Rx, in two clinical studies in patients with advanced lymphoma and metastatic liver cancer.

Read more here:

http://www.heraldonline.com/2013/06/03/4913337/isis-pharmaceuticals-reports-encouraging.html

 

volleyball

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

Share

Selumetinib is the first drug ever to show significant benefit for patients with advanced uveal melanoma

 Uncategorized  Comments Off on Selumetinib is the first drug ever to show significant benefit for patients with advanced uveal melanoma
Jun 042013
 

Two Array Invented MEK Inhibitors Showcased At ASCO
Sacramento Bee
AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.

http://www.sacbee.com/2013/06/03/5466446/two-array-invented-mek-inhibitors.html

Two Array BioPharma-invented MEK inhibitors, selumetinib and MEK162, were showcased at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).

 

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

 

Share

Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease,

 drugs  Comments Off on Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease,
Jun 032013
 

World First Hand' Foot And Mouth Vaccine Developed

AsianScientist (Jun. 3, 2013) – By Sunanda Creagh – Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease, a condition commonly affecting small children that can lead to deadly infection of the brain and spinal cord membranes.

read all at

http://www.asianscientist.com/health-medicine/world-hand-foot-mouth-vaccine-developed-2013/

Share

GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)

 drugs  Comments Off on GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)
Jun 012013
 

may30,2013–GlaxoSmithKline (GSK) and Genmab (GEN) have announced positive results from Phase III study of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of chronic lymphocytic leukaemia (CLL) patients.

Share

Discovery of Unexpectedly Active Group-Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off

 Uncategorized  Comments Off on Discovery of Unexpectedly Active Group-Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off
May 312013
 

thumbnail image: Discovery of Unexpectedly Active Group

Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off

Read more

Share

Study: Lilly’s Forteo Increases Bone Mineral Density in Men

 drugs  Comments Off on Study: Lilly’s Forteo Increases Bone Mineral Density in Men
May 312013
 

FORTEO (teriparatide [rDNA origin]) Structural Formula Illustration

New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis

http://www.pharmalive.com/study-lillys-forteo-increases-bone-mineral-density-in-men

Share
 Older Entries  Newer Entries
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: